Journal article
Crizotinib in ROS1-rearranged non-small-cell lung cancer
AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, M Varella-Garcia, GI Shapiro, DB Costa, RC Doebele, LP Le, Z Zheng, W Tan, P Stephenson, SM Shreeve, LM Tye, JG Christensen, KD Wilner, JW Clark Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2014
Abstract
Background: Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non-small-cell lung cancers (NSCLCs) that may be susceptible to therapeutic ROS1 kinase inhibition. Crizotinib is a small-molecule tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and another proto-oncogene receptor tyrosine kinase, MET. Methods: We enrolled 50 patients with advanced NSCLC who tested positive for ROS1 rearrangement in an expansion cohort of the phase 1 study of crizotinib. Patients were treated with crizotinib at the standard oral dose of 250 mg twice daily and assessed for safety, pharmacokinetics, and re..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
Supported by Pfizer, by grants from the National Cancer Institute (R21CA161590, to Dr. Iafrate; K12CA086913, to Dr. Doebele; P50CA058187, to Drs. Doebele and Camidge; and P30CA046934, to Dr. Varella-Garcia), by a research grant from Uniting against Lung Cancer (to Dr. Shaw), by the Swedish Research Council (postdoctoral fellowship 350-2012-368, to Dr. Zheng), and by Be a Piece of the Solution.